Glaukos Corp director Gilbert H. Kliman filed a Form 144 notice on November 4, 2026, disclosing a proposed sale of 2,500 shares of Glaukos common stock through Fidelity Brokerage Services LLC on the New York Stock Exchange.

Key Highlights

  • Proposed sale: Gilbert H. Kliman, a director of Glaukos Corp (NYSE:GKOS), intends to sell 2,500 shares of common stock.
  • Aggregate market value: The proposed sale carries an aggregate market value of $632,500.00, according to the filing.
  • Shares outstanding: The filing reports 59,196,870 shares of Glaukos common stock outstanding at the time of notice.
  • Acquisition method: The 2,500 shares were acquired on November 4, 2026, via a stock option exercise from the issuer, with compensation listed as the nature of payment.
  • Prior three-month sales: Kliman sold 2,500 shares on August 19, 2026, generating gross proceeds of $475,000.00, as reported in the filing's prior-sales section.
  • Broker named: Fidelity Brokerage Services LLC, located at 900 Salem Street, Smithfield, Rhode Island 02917, is the designated broker for the proposed transaction.

Kliman's Stock Option Exercise and Proposed Common Stock Sale at Glaukos

Glaukos Corp, an ophthalmic medical device and pharmaceutical company headquartered at 1 Glaukos Way, Aliso Viejo, California, is the issuer identified in this Form 144 notice. The filing was submitted by director Gilbert H. Kliman, who proposes to sell 2,500 shares of Glaukos common stock, with an approximate sale date of November 4, 2026, on the NYSE. According to the filing, the shares were acquired the same day through a stock option exercise directly from the issuer, with compensation cited as the nature of payment.

The aggregate market value of the proposed sale is listed in the filing as $632,500.00 for the 2,500 shares, against a total of 59,196,870 shares of Glaukos common stock reported as outstanding. The notice was signed by Daniel Tucci as a duly authorized representative of Fidelity Brokerage Services LLC, acting as attorney-in-fact for Gilbert Kliman. The filing also discloses that Kliman sold 2,500 shares of Glaukos common stock on August 19, 2026, for gross proceeds of $475,000.00, the only prior transaction reported within the preceding three-month window required by Form 144.

As required by Form 144, Kliman represented by signing the notice that he "does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed," according to the filing's attestation language.

What Was Disclosed

Glaukos Corp director Gilbert H. Kliman filed a Form 144 notice proposing the sale of 2,500 shares of common stock with an aggregate market value of $632,500.00. The shares were acquired through a stock option exercise on November 4, 2026, and the proposed sale is to be executed on the NYSE via Fidelity Brokerage Services LLC.